ASYMMETRYBETA
Loading LEGN...
Legend Biotech Corp.LEGNAs of 31 July 2026
Trailing (TTM)
Price to earnings·
Price to sales·
Price to book·
Price to op. cash flow·
Price to free cash flow·
Forward P/S (NTM)
Forward P/S (Y1)·
Forward P/S (Y2)·
Forward P/S (Y3)·
Forward P/S (Y4)·
Forward P/S (Y5)·
Forward P/E (NTM)
Forward P/E (Y1)·
Forward P/E (Y2)·
Forward P/E (Y3)·
Forward P/E (Y4)·
Forward P/E (Y5)·
Forward EV/EBIT (NTM)
Forward EV/EBIT (Y1)·
Forward EV/EBIT (Y2)·
Forward EV/EBIT (Y3)·
Forward EV/EBIT (Y4)·
Forward EV/EBIT (Y5)·
−300−1500+150+300
−204
PositiveNegative
Positive asymmetry
Valuation−95
CheapExpensive
Emotion−98
FearGreed
Fundamentals+11
WeakStrong
Valuation

Is Legend Biotech Corp. undervalued or overvalued?

Where Legend Biotech Corp. (LEGN) trades across 21 valuation metrics, from price-to-sales and forward P/E to book and cash-flow multiples, each ranked against its own five-year history rather than a broad sector average, so you can see whether it is genuinely cheap or expensive on its own terms. Information, not advice.

Legend Biotech Corp.LEGNLast 5 years
V—E—F—A—
——
LEGN priceasymmetryquant.com
A Asymmetry—
V Valuation—
E Emotion—
F Fundamentals—